Sugi Predict

Sugi Predict / Compounds / SCHEMBL1104909

SCHEMBL1104909

SCHEMBL1104909

CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)[C@H]1CO1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.54
▸ CTSS P25774 3/20 0.52
▸ CTSK P43235 2/20 0.52
▸ CTSL P07711 1/20 0.52
▸ CTSB P07858 1/20 0.52
▸ ACE P12821 2/20 0.50
▸ KLK5 Q9Y337 4/20 0.48
▸ KLK7 P49862 4/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ XBP1 P17861 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865405 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL2079109 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL4974304 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL2983027 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL496136 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL7438571 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL2983024 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL639229 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
Butylbenzyl SCHEMBL8490527 0.91 CTSK (0.50) ATMCTSSCTSKCTSLCTSB
Butylbenzyl SCHEMBL8487457 0.91 CTSK (0.50) ATMCTSSCTSKCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119708491-A Polydisulfide polymer material containing hydroxy ester group and preparation method thereof 衢州化工新材料创新研究院 2025-03-28 — — CN claimed
CN-114907240-A Production method of darunavir intermediate 浙江江北药业有限公司 2022-08-16 — — CN claimed
CN-113004227-A Synthesis method of (2S,3S) -3- (tert-butyloxycarbonylamino) -1, 2-epoxy-4-phenylbutane 常州吉恩药业有限公司 2021-06-22 — — CN claimed
US-6737264-B1 (2S,3S)-1-HALO-2-HYDROXY-3-N-(TERT-BUTOXYCARBONYL)AMINO-4-PHEN YLBUTANE; (2R,3S)-1-HALO-2-HYDROXY-3-N-(TERT-BUTOXYCARBONYL) AMINO-4-PHENYLBUTANE; USED AS PRODUCTION INTERMEDIATES HIV PROTEASE INHIBITORS KANEKA CORPORATION (JP) 2004-05-18 — — US claimed
EP-1151992-B1 METHOD FOR PURIFYING AND ISOLATING (2S,3S)- OR (2R,3S)-HALOHYDRIN DERIVATIVES KANEKA CORP (JP) 2003-09-17 — — EP claimed
EP-1151992-A1 METHOD FOR PURIFYING AND ISOLATING (2S,3S)- OR (2R,3S)-HALOHYDRIN DERIVATIVES KANEKA CORPORATION (JP) 2001-11-07 — — EP claimed
US-20260014174-A1 DUAL INHIBITORS FOR HDAC3 AND HIV-1 PR PURDUE RESEARCH FOUNDATION (US) 2026-01-15 — — US disclosed
CN-119708491-A Polydisulfide polymer material containing hydroxy ester group and preparation method thereof 衢州化工新材料创新研究院 2025-03-28 — — CN disclosed
WO-2025028284-A1 RESIN COMPOSITION, CURED ARTICLE, AND METHOD FOR PRODUCING CURED ARTICLE 株式会社ADEKA 2025-02-06 — — WO disclosed
CN-118638078-A Darunavir intermediate Process for the preparation of intermediates 江苏八巨药业有限公司 2024-09-13 — — CN disclosed
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2024-08-08 — — US disclosed
CN-116042002-B Conductive polymer dispersion, conductive polymer-containing liquid, conductive laminate, capacitor, and method for producing these 信越聚合物株式会社 2024-06-11 — — CN disclosed
CN-118173384-A Conductive polymer dispersion, conductive polymer-containing liquid, conductive laminate, capacitor, and method for producing these 信越聚合物株式会社 2024-06-11 — — CN disclosed
WO-1997042180-A1 PROCESS FOR PREPARING OXIRANEMETHANAMINE DERIVATIVES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1997-11-13 — — WO disclosed
EP-0796239-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (S,S) AMINOEPOXIDES, KEY INTERMEDIATES FOR HIV PROTEASE INHIBITORS, VIA THEIR CHLOROHYDRINES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1997-09-24 — — EP disclosed
US-5550291-A Process for key intermediates for HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) 1996-08-27 — — US disclosed
US-5550291-A Process for key intermediates for HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) 1996-08-27 — — US disclosed
WO-1996017821-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (S,S) AMINOEPOXIDES, KEY INTERMEDIATES FOR HIV PROTEASE INHIBITORS, VIA THEIR CHLOROHYDRINES BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE (CA) 1996-06-13 — — WO disclosed
US-5488118-A Process for producing optically active erythro-3-amino-1,2-epoxy compound NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1996-01-30 — — US disclosed
EP-0657446-A1 Process for producing optically active erythro-3-amino-1,2-epoxy compound NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1995-06-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014174-A1 DUAL INHIBITORS FOR HDAC3 AND HIV-1 PR HDAC3, HDAC1, HDAC11 ATM 2320/4885CTSS 125/4885CTSK 471/4885
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 ATM 1438/4885CTSS 2213/4885CTSK 2165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.